Abstracts tagged "registries and rheumatoid arthritis (RA)"

Abstract Number: 227 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patients Treated with Abatacept, Rituximab and Tocilizumab in Denmark and Sweden: Risk of Serious Infections
Kathrine Lederballe Grøn¹, Elizabeth V. Arkema², Bente Glintborg¹, Frank Mehnert³, Mikkel Østergaard⁴, Lene Dreyer⁵, Mette Nørgaard³, Niels Steen Krogh⁶, Johan Askling⁷ and Merete Lund Hetland⁸, ¹The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ²Clinical Epidemiology Unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ³Aarhus University Hospital, Clinical Epidemiological Department, Aarhus, Denmark, ⁴The DANBIO registry and the Danish Departments of Rheumatology, Glostrup, Denmark, ⁵Departments of Rheumatology and Clinical Medicine, Aalborg University Hospital and Aalborg University, 9000 Aalborg, Denmark, ⁶ZiteLab ApS, Copenhagen, Denmark, ⁷Unit of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ⁸DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Glostrup, Denmark
Background/Purpose: Safety concerns have been raised regarding the risk of serious infections (SI) with the different available biologic disease-modifying anti-rheumatic drugs (bDMARDs). Little is known…
Abstract Number: 2857 • 2018 ACR/ARHP Annual Meeting
An Electronic Audit, Reporting, and Data Correction System Improves the Quantity and Quality of Observational Data Collected for US Veterans Enrolled in the Veterans Affairs Rheumatoid Arthritis Registry
Grant W. Cannon^1,2, Jorge Rogas², Neill Bell³, Joshua Baker⁴, Gail S. Kerr⁵, Angelo Gaffo⁶, J. Steuart Richards⁷, Jennifer Barton⁸, Pascale Schwab⁸, Ted R. Mikuls⁹, Namrata Singh¹⁰, Liron Caplan¹¹, Deana Lazaro¹², Andreas Reimold¹³ and Brian Sauer², ¹Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³Salt Lake City VA Medical Center and University of Utah, Dallas VA Medical Center, Dallas, TX, ⁴Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, PA, ⁵Washington VA Medical Center, Georgetown and Howard Universities, Washington, DC, ⁶Birmingham VA and University of Alabama at Birmingham, Birmingham, AL, ⁷Pittsburgh VA Medical Center and University of Pittsburgh, Pittsburgh, PA, ⁸VA Portland Health Care System and Oregon Health and Science, Portland, OR, ⁹VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ¹⁰Internal Medicine, Iowa City VA Medical Center and University of Iowa, Iowa City, IA, ¹¹Div of Rheumatology, Denver VA Medical Center and University of Colorado, Aurora, CO, ¹²Brooklyn VA Medical Center and SUNY Downstate, Brooklyn, NY, ¹³Rheumatology, Dallas VA Medical Center and University of Texas - Southwestern, Dallas, TX
Background/Purpose: The Veterans Affairs (VA) Rheumatoid Arthritis (RA) (VARA) registry is an observational cohort study of US Veterans with RA at 11 VA Medical…
Abstract Number: 541 • 2017 ACR/ARHP Annual Meeting
Decreasing Trend of Serious Infections Incidence Rate Along Years in Rheumatoid Arthritis Patients Exposed to Biologics. Data from Two Latin America Registries
Roberto Ranza¹, Ieda Maria Magalhães Laurindo², Georges Christopoulos², Gimena Gomez³, Enrique R Soriano⁴, Miguel Angel Descalzo⁵ and Maria de la Vega⁶, ¹on behalf of the BiobadaBrasil study group, Sociedade Brasileira de Reumatologia, Uberlandia, Brazil, ²on behalf of the BiobadaBrasil study group, Sociedade Brasileira de Reumatologia, São Paulo, Brazil, ³on behalf of BiobadaSar study group, Sociedad Argentina de Reumatologia, Buenos Aires, Argentina, ⁴Argentina, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Research Unit, Fundacion piel sana AEDV, Madrid, Spain, Madrid, Spain, ⁶on behalf of BiobadaSar study group, Sociedad Argentina de Reumatologia, Buenos aires, Argentina
Background/Purpose: Infections are the most frequent and concerning serious adverse events related to rheumatoid arthritis (RA) treatment with biologic drugs (bDMARDs). Their safety profile might…
Abstract Number: 1442 • 2017 ACR/ARHP Annual Meeting
Corticosteroid Sparing Effect of Non-TNF Targeted Biologics, Rituximab, Abatacept and Tocilizumab in Common Practice: Data from 3183 Patients Enrolled in the French Society of Rheumatology Registries
Jacques-Eric Gottenberg¹, Jacques Morel², Arnaud Constantin³, Thomas Bardin⁴, Alain Cantagrel⁵, Bernard Combe², Maxime Dougados⁶, René-Marc Flipo⁷, Alain Saraux⁸, Thierry Schaeverbeke⁹, Jean Sibilia¹⁰, Martin Soubrier¹¹, Olivier Vittecoq^12,13, Gabriel Baron¹⁴, Elodie Perrodeau¹⁵, Philippe Ravaud¹⁴ and Xavier Mariette¹⁶, ¹CNRS, Immunopathologie et Chimie Thérapeutique/Laboratory of Excellence Medalis, Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France, ²Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, ³Rheumatology, CHU Purpan - Hopital Pierre-Paul Riquet, Toulouse, France, ⁴Clinique de Rhumatologie, Hopital Lariboisiere, Paris Cedex 10, France, ⁵Department of Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, Toulouse, France, ⁶Rheumatology, Paris Descartes University, Paris, France, ⁷Rheumatology, Department of Rheumatology, CHU Teaching Hospital Lille, France., Lille, France, ⁸Rheumatology, Brest University Hospital, Brest, France, ⁹Department of Rheumatology, Bordeaux University Hospital, BORDEAUX, France, ¹⁰Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹¹Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹²INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France, ¹³Rheumatology Department and INSERM U 905, CHU Rouen, Rouen, France, ¹⁴Hôpital Hôtel Dieu, Paris, France, ¹⁵Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ¹⁶Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France
Background/Purpose: Little is known regarding the corticosteroid sparing effect of non-TNF biologics in rheumatoid arthritis (RA). Objectives : To compare the corticosteroid sparing effect of…
Abstract Number: 1406 • 2016 ACR/ARHP Annual Meeting
Towards Harmonized Data Collection in Rheumatoid Arthritis (RA): The EULAR Task Force for Standardizing a Minimum Data Collection for RA Observational Research
Helga Radner¹, Elena Nikiphorou², Katerina Chatzidionysiou³, Laure Gossec⁴, Kimme L. Hyrich⁵, Codruta Zăbălan⁶, Yvonne JL van Eijk-Hustings⁷, Paula Williamson⁸, William G Dixon⁹, Johan Askling¹⁰ and The EULAR Task Force for standardising minimum data collection in Rheumatoid Arthritis observational research, ¹Rheumatology, Medical University of Vienna, Vienna, Austria, ²Whittington Hospital, London, United Kingdom, ³Department of Medicine, Unit of Rheumatology, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Paris 06 University and AP-HP, Hôpital Pitié Salpêtrière, Paris, France, ⁵Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁶Romanian League against Rheumatism, BUCHAREST, Romania, ⁷Patient&Care, Maastricht University Medical Centre, Maastricht, Netherlands, ⁸Clinical Trials Research Centre, University of Liverpool, Liverpool, United Kingdom, ⁹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, Great Britain, ¹⁰Dept. of Medicine, Rheumatology Unit & Clinical Epidemiology Unit, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Collaborative research is compromised by heterogeneity of data collection in observational rheumatoid arthritis (RA) databases. Therefore a EULAR taskforce has been convened to develop…
Abstract Number: 2527 • 2016 ACR/ARHP Annual Meeting
Drug Retention of Biologics in Rheumatoid Arthritis Patients: The Role of Baseline Characteristics and Impact of Time-Varying Factors
Delphine Courvoisier¹, Deshire Alpizar Rodriguez², Jacques-Eric Gottenberg³, Florenzo Iannone⁴, Elisabeth Lie⁵, Maria José Santos⁶, Karel Pavelka⁷, Merete Lund Hetland⁸, Carl Turesson⁹, Xavier Mariette¹⁰, Denis Choquette¹¹ and Axel Finckh¹², ¹University hospital of Geneva, Geneva, Switzerland, ²Rheumatology, University Hospitals of Geneva, Geneva, Switzerland, ³Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁴Reumatologia Universita e Policlinico di Bari, Bari, Italy, ⁵Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Reumatologia, Hospital Garcia de Orta, Almada, Portugal, ⁷Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ⁹Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ¹⁰INSERM U1184, Université Paris-Sud, Paris, France, Le Kremlin Bicetre, France, ¹¹Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ¹²Rheumatology Division, University Hospital of Geneva, Geneva, Switzerland
DRUG RETENTION OF BIOLOGICS IN RHEUMATOID ARTHRITIS PATIENTS: THE ROLE OF BASELINE CHARACTERISTICS AND IMPACT OF TIME-VARYING FACTORS D.S. Courvoisier1, D. Alpizar-Rodriguez1, JE. Gottenberg2, F. Iannone4,…
Abstract Number: 427 • 2015 ACR/ARHP Annual Meeting
The Impact of Biologic Agent Initiation after 1 Versus 2 Prior Csdmards in Patients with Rheumatoid Arthritis
Dimitrios A. Pappas^1,2, Jenny Griffith³, Chitra Karki², Mei Liu⁴, Joel M. Kremer⁵, Arijit Ganguli³ and Jeffrey D. Greenberg^2,6, ¹Columbia University, New York, NY, ²Corrona, LLC, Southborough, MA, ³AbbVie Inc., North Chicago, IL, ⁴352 Turnpike Rd, Corrona, LLC, Southborough, MA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY, ⁶NYU School of Medicine, New York, NY
Background/Purpose: Patients with Rheumatoid Arthritis (RA) who don’t respond to conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) should be treated with biologic agents(1). The objective…
Abstract Number: 2521 • 2015 ACR/ARHP Annual Meeting
Pregnancies in Patients with Long-Standing Rheumatoid Arthritis and Biologic DMARD Treatment: Course of Disease during Pregnancy and Pregnancy Outcomes
Anja Strangfeld¹, Dagmar Pattloch¹, Madlen Spilka², Bernhard Manger³, Brigitte Krummel-Lorenz⁴, Annett Gräßler⁵, Joachim Listing⁶ and Angela Zink^1,7, ¹Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Rheumatologist, Scientific Advisory Board, Erlangen, Germany, ⁴Rheumatologist, Frankfurt, Germany, ⁵Rheumatologist, Pirna, Germany, ⁶Epidemiologiy, German Rheumatism Research Center, Berlin, Germany, ⁷Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany
Background/Purpose: The assumption of spontaneous remission among pregnant women with rheumatoid arthritis (RA) is common. Nevertheless, prospectively collected data describing the course of disease activity…
Abstract Number: 2525 • 2014 ACR/ARHP Annual Meeting
Infliximab Versus Conventional Combination Treatment and Work Loss in Early RA over 7 Years: A Randomized Trial
Jonas K Eriksson¹, Heather Miller², Johan A Karlsson³, Ingemar F Petersson⁴, Sofia Ernestam⁵, Pierre Geborek³, Ronald F van Vollenhoven² and Martin Neovius¹, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²ClinTRID, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ³Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁴Section of Orthopedics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁵Department of Learning, Informatics and Medical Education (LIME), Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The introduction of TNF inhibitors has improved the treatment of RA, but at a substantial cost. The randomized Swefot trial compared the addition of…
Abstract Number: 2367 • 2014 ACR/ARHP Annual Meeting
Physician Awareness of Suboptimal Patient Adherence to MTX: Results from a Large U.S. Rheumatoid Arthritis Registry
Jeffrey R. Curtis¹, Aseem Bharat², Lang Chen³, Jeffrey D. Greenberg⁴, Joel M. Kremer⁵ and Dimitrios A. Pappas⁴, ¹Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Corrona, LLC., Southborough, MA, ⁵Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY
Background/Purpose: Most rheumatoid arthritis (RA) registries capture information about medication use using data captured at office visits. The extent to which this information may be…
Abstract Number: 1071 • 2014 ACR/ARHP Annual Meeting
What Is the Impact of Chronic Systemic Inflammation Such As Rheumatoid Arthritis on Mortality Following Cancer?
Julia Simard^1,2, Sara Ekberg³, Anna Johansson⁴ and Johan Askling^2,5, ¹Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA, ²Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ³Dept of Medical Epidemiology of Biostatistic, Karolinska Institutet, Stockholm, Sweden, ⁴Dept of Medical Epidemiology and Biostatistics, Karolinska Institutet, stockholm, Sweden, ⁵Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Emerging evidence links inflammation and immune-competence to cancer progression and outcome. The few studies addressing cancer survival in the context of systemic inflammation,…
Abstract Number: 2910 • 2013 ACR/ARHP Annual Meeting
Differences In Abatacept Use In Rheumatoid Arthritis Patients Across Europe: A Pan-European Database Analysis Of Abatacept In European RA Registries
David Neto¹, Axel Finckh², Florenzo Iannone³, Estíbaliz Loza⁴, Elisabeth Lie⁵, Piet L.C. Van Riel⁶, Merete L. Hetland⁷, Karel Pavelka⁸, Jacques-Eric Gottenberg⁹, Xavier Mariette¹⁰ and Carl Turesson¹¹, ¹University of Geneva, Geneva, Switzerland, ²Rheumatology, Geneva University Hospital, Geneva, Switzerland, ³D.I.M.I.M.P, Rheumatology Unit - University of Bari, Bari, Italy, ⁴Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ⁵Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁷Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ⁸Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, ⁹Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ¹⁰Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, ¹¹Department of Rheumatology, Skåne University Hospital, Malmö, Sweden
Background/Purpose: Several European registries have pooled data of patients (pts) who received Abatacept (ABA) for rheumatoid arthritis (RA) to acquire new knowledge about performance of…
Abstract Number: 1514 • 2013 ACR/ARHP Annual Meeting
Drug Survival In Patients Receiving Golimumab Treatment 2010-2013. Results From The Swedish Rheumatology Quality Register
Saedis Saevarsdottir¹, Michele Santacatterina², Leszek Stawiarz³, Carl Turesson⁴, Helena Forsblad⁵, Lennart T.H. Jacobsson⁶ and Staffan Lindblad⁷, ¹Rheumatology Unit, Dept. of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ²Biostatistics Core Facility, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, ⁴Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁵Dept of Rheumatology & Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁶Department of Rheumatology and Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁷Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Golimumab is a TNF inhibiting biological drug that was approved in Sweden in 2010 for the treatment of Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)…
Abstract Number: 1483 • 2013 ACR/ARHP Annual Meeting
Physician and Patient Characteristics Associated With The Decision To Treat Rheumatoid Arthritis Patients With Biologic Monotherapy In Usual Care Settings
Mariely Nieves-Plaza¹, Heather Eng², Ilinca D. Metes³, Ashwini Shewede⁴, Stephen R. Wisniewski², Ani John⁴ and Marc C. Levesque⁵, ¹Clinical And Translational Science Institute, Univeristy of Pittsburgh, Pittsburgh, PA, ²Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ³Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Genentech Inc., South San Francisco, CA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA
Background/Purpose: Approximately 30% of rheumatoid arthritis (RA) patients treated with a biologic, receive the biologic as monotherapy i.e. without concomitant oral disease modifying anti-rheumatic drugs…
Abstract Number: 1425 • 2013 ACR/ARHP Annual Meeting
Discontinuation Of Tumor Necrosis Factor Inhibitors In Rheumatoid Arthritis Patients In Low Disease Activity: Persistent Benefits
Arthur Kavanaugh¹, Susan J. Lee^2,3, Daniel H. Solomon⁴, Jeffrey D. Greenberg⁵, Joel M. Kremer⁶, Lilian Soto⁷, Carol J. Etzel^8,9 and George W. Reed¹⁰, ¹University of California, San Diego, La Jolla, CA, ²University of California San Diego, La Jolla, CA, ³San Diego Veterans Affairs Medical Center, San Diego, CA, ⁴Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁵NYU Hospital for Joint Diseases, New York, NY, ⁶Center for Rheumatology, Albany Medical College, Albany, NY, ⁷University of California San Diego, San Diego, CA, ⁸Department of Epidemiology, UT MD Anderson, Houston, TX, ⁹PO Box 786, Corrona, LLC., Southborough, MA, ¹⁰Corrona, LLC., Southborough, MA
Background/Purpose: A key question is whether biologic agents can be stopped but clinical benefit maintained for rheumatoid arthritis (RA) patients (pts) in remission or low…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].